Zomedica Launches New Cortisol Assay for Equine Health on TRUFORMA Platform
Portfolio Pulse from Benzinga Newsdesk
Zomedica Corp. (NYSE:ZOM) has launched a new cortisol assay for equine health on its TRUFORMA diagnostic platform. This new tool allows equine veterinarians to measure cortisol levels in foals at the point of care, enabling real-time, potentially life-saving treatment decisions. The TRUFORMA platform addresses a $1.5 billion annual recurring revenue opportunity in the US and is expanding into the European market.
June 27, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zomedica has launched a new cortisol assay for equine health on its TRUFORMA platform, enhancing its product offerings and expanding its market opportunity in the US and Europe.
The launch of the new cortisol assay for equine health on the TRUFORMA platform is likely to positively impact Zomedica's stock price in the short term. This product enhances their diagnostic offerings and addresses a significant market opportunity, both in the US and Europe.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100